Traditional CNS drugs flood the entire body to reach a small area of the brain. Captons® are engineered to do the opposite: they remain inactive until they reach the site of disease.
Our platform began with a routine experiment that didn't behave as expected. What looked like an anomaly turned out to be a previously unrecognized chemical mechanism: one that allows a molecule to stay dormant in healthy tissue, and activate only when it encounters the chemical signature of disease itself.
That observation became the foundation of Capton® technology: therapies designed to let pathology switch on their own activation, precisely where treatment is needed.
Captons® are administered in an inactive form. In the presence of the reactive byproducts of neuropathology, they convert into their therapeutic form, and nowhere else.
Elevated oxidative activity and free metal ions are characteristic of damaged or diseased brain tissue, but largely absent from healthy tissue. Captons® are designed to convert to their active form only in that environment, sparing everything else.
Capton® technology is designed to address oxidative stress–driven disease biology. We are initially focused on therapeutic applications in:
Most CNS drugs are active the moment they enter the body. Captons® are built to wait.
Small, lipophilic molecules designed to reach the brain, where most CNS drugs fail to penetrate.
Remains inert in healthy tissue, activating only in the presence of injury or disease chemistry.
By acting only where it's needed, Captons® are designed to reduce off-target effects.
Capton® technology was discovered and developed by a small team of chemists and neuroscientists with decades of CNS drug development experience.
Meet the Team